ATE267015T1 - Verbindungen und verfahren zur behandlung von krebs - Google Patents

Verbindungen und verfahren zur behandlung von krebs

Info

Publication number
ATE267015T1
ATE267015T1 AT95933071T AT95933071T ATE267015T1 AT E267015 T1 ATE267015 T1 AT E267015T1 AT 95933071 T AT95933071 T AT 95933071T AT 95933071 T AT95933071 T AT 95933071T AT E267015 T1 ATE267015 T1 AT E267015T1
Authority
AT
Austria
Prior art keywords
compounds
methods
treating cancer
cancer
treating
Prior art date
Application number
AT95933071T
Other languages
English (en)
Inventor
Chung K Chu
Yung-Chi Cheng
Original Assignee
Univ Georgia Res Found
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia Res Found, Univ Yale filed Critical Univ Georgia Res Found
Application granted granted Critical
Publication of ATE267015T1 publication Critical patent/ATE267015T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT95933071T 1994-09-06 1995-09-05 Verbindungen und verfahren zur behandlung von krebs ATE267015T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE267015T1 true ATE267015T1 (de) 2004-06-15

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933071T ATE267015T1 (de) 1994-09-06 1995-09-05 Verbindungen und verfahren zur behandlung von krebs

Country Status (31)

Country Link
US (3) US6063787A (de)
EP (2) EP1468687A1 (de)
JP (1) JP3979662B2 (de)
KR (1) KR100374477B1 (de)
CN (3) CN1827108A (de)
AP (1) AP783A (de)
AT (1) ATE267015T1 (de)
AU (1) AU704977B2 (de)
BG (1) BG63122B1 (de)
BR (1) BR9508886A (de)
CA (1) CA2199117C (de)
CZ (1) CZ297873B6 (de)
DE (1) DE69533066T2 (de)
DK (1) DK0781136T3 (de)
ES (1) ES2219666T3 (de)
FI (1) FI970918A7 (de)
HU (1) HUT77172A (de)
IL (1) IL115156A (de)
IS (1) IS2011B (de)
MY (1) MY121548A (de)
NO (1) NO313268B1 (de)
NZ (1) NZ335013A (de)
OA (1) OA10473A (de)
PL (2) PL189288B1 (de)
PT (1) PT781136E (de)
RO (1) RO118748B1 (de)
RU (1) RU2168995C2 (de)
SI (1) SI0781136T1 (de)
SK (1) SK284564B6 (de)
WO (1) WO1996007413A1 (de)
ZA (1) ZA957483B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
AU9016998A (en) 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
AU753155B2 (en) 1998-01-23 2002-10-10 Kiadis Pharma Intellectual Property B.V. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
EP1058686B1 (de) 1998-02-25 2006-11-02 Emory University 2'-fluoronukleoside
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
EP1165096B1 (de) * 1999-03-29 2009-09-09 Shire Canada Inc. Verwendung von cytidinderivaten zur behandlung von leukämie
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
DE60011637T2 (de) 1999-09-24 2004-11-11 Shire Biochem Inc., Laval Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1634888A3 (de) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthese von 2'-Deoxy-L-Nukleosiden
MXPA03003278A (es) * 2000-10-13 2005-07-01 Shire Biochem Inc Analogos de dioxolano para suministro intercelular mejorado.
EP1359921A4 (de) 2001-01-19 2006-09-06 Newbiotics Inc Verfahren zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen
KR20040018341A (ko) 2001-03-23 2004-03-03 샤이어 바이오켐 인코포레이티드 암치료용 약제 조성물
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
US20030027799A1 (en) * 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
AU2002336864B2 (en) * 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
BRPI0214256B8 (pt) * 2001-11-19 2021-05-25 Medigene Ag medicamento
KR100582957B1 (ko) 2002-06-21 2006-05-23 엘지전자 주식회사 비디오 데이터의 재생을 관리하기 위한 데이터 구조를 갖는기록 매체
AU2003241198B2 (en) 2002-06-21 2009-09-03 Lg Electronics Inc. Recording medium having data structure for managing reproduction of video data recorded thereon
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
RU2309467C2 (ru) 2002-06-24 2007-10-27 Эл Джи Электроникс Инк. Носитель записи со структурой данных, включающей навигационно-управляющую информацию, для управления воспроизведением записанных на нем видеоданных и способы и устройства записи и воспроизведения
WO2004003908A1 (en) 2002-06-28 2004-01-08 Lg Electronics Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
JP2006502195A (ja) * 2002-09-24 2006-01-19 ノバルティス アクチエンゲゼルシャフト 骨髄異形成症候群の処置用医薬の製造のための4−ピリジルメチル−フタラジン誘導体の使用
RU2347284C2 (ru) 2002-10-14 2009-02-20 Эл Джи Электроникс Инк. Носитель записи со структурой данных для управления воспроизведением записанного на нем множества аудиопотоков и способы и устройства записи и воспроизведения
CA2469178C (en) 2002-10-15 2009-09-01 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple graphics streams recorded thereon and recording and reproducing methods and apparatuses
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7570866B2 (en) 2002-11-12 2009-08-04 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7606463B2 (en) 2003-02-24 2009-10-20 Lg Electronics, Inc. Recording medium having data structure for managing playback control and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
CN100397882C (zh) 2003-02-28 2008-06-25 Lg电子株式会社 具有用于管理记录其上的视频数据的随机/洗牌重现的数据结构的记录媒体以及记录和重现的方法和装置
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
AU2004281525B2 (en) 2003-10-09 2010-01-28 Aresus Pharma GmbH The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
CA2609343C (en) * 2005-06-07 2015-03-31 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
EP1968595A4 (de) * 2005-12-02 2014-05-21 Univ Yale Verfahren zur behandlung von krebs und anderer zustände oder erkrankungen mit l-cytosin-nucleosid-analoga
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
RU2322243C1 (ru) * 2006-10-20 2008-04-20 Наталья Юрьевна Костюкова Фармацевтическая композиция для лечения поражений роговицы
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
EP3562946B1 (de) * 2016-12-28 2021-11-24 Transgene SA Onkolytische viren und therapeutische moleküle
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
IN164556B (de) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
DE3850571T2 (de) * 1987-03-24 1994-10-27 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate.
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
CA2005815C (en) * 1988-12-19 1999-08-03 Wellcome Foundation Limited (The) Antiviral acyclic nucleoside derivatives
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995018137A1 (en) * 1993-12-30 1995-07-06 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
JP3979662B2 (ja) 2007-09-19
ES2219666T3 (es) 2004-12-01
BG63122B1 (bg) 2001-04-30
IL115156A (en) 2000-07-16
EP0781136A1 (de) 1997-07-02
NO971015D0 (no) 1997-03-05
AU704977B2 (en) 1999-05-13
DK0781136T3 (da) 2004-08-02
FI970918A0 (fi) 1997-03-04
OA10473A (en) 2002-04-08
MY121548A (en) 2006-02-28
ZA957483B (en) 1997-06-06
US20050261320A1 (en) 2005-11-24
CA2199117C (en) 2006-04-11
KR970705393A (ko) 1997-10-09
HUT77172A (hu) 1998-03-02
IL115156A0 (en) 1995-12-31
US6063787A (en) 2000-05-16
NO313268B1 (no) 2002-09-09
JPH10506385A (ja) 1998-06-23
IS2011B (is) 2005-05-13
CZ297873B6 (cs) 2007-04-18
IS4434A (is) 1997-03-04
SK28197A3 (en) 1997-09-10
US8076347B2 (en) 2011-12-13
AP9700939A0 (en) 1997-04-30
FI970918L (fi) 1997-05-02
EP0781136A4 (de) 1999-06-23
WO1996007413A1 (en) 1996-03-14
PT781136E (pt) 2004-09-30
PL188359B1 (pl) 2005-01-31
BR9508886A (pt) 1997-12-30
NZ335013A (en) 2000-07-28
RU2168995C2 (ru) 2001-06-20
CN1827108A (zh) 2006-09-06
CN1111409C (zh) 2003-06-18
DE69533066T2 (de) 2005-06-02
US20080171758A1 (en) 2008-07-17
CZ63397A3 (en) 1997-07-16
EP1468687A1 (de) 2004-10-20
EP0781136B1 (de) 2004-05-19
SI0781136T1 (en) 2004-08-31
CN1251680C (zh) 2006-04-19
CN1448142A (zh) 2003-10-15
FI970918A7 (fi) 1997-05-02
AU3586295A (en) 1996-03-27
US7262213B2 (en) 2007-08-28
NO971015L (no) 1997-03-05
CA2199117A1 (en) 1996-03-14
PL318971A1 (en) 1997-07-21
BG101284A (bg) 1998-03-31
KR100374477B1 (ko) 2003-06-19
DE69533066D1 (de) 2004-06-24
CN1160351A (zh) 1997-09-24
SK284564B6 (sk) 2005-06-02
RO118748B1 (ro) 2003-10-30
AP783A (en) 1999-11-17
PL189288B1 (pl) 2005-07-29

Similar Documents

Publication Publication Date Title
DE69533066D1 (de) Verbindungen und verfahren zur behandlung von krebs
ATE230606T1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69425372D1 (de) Verfahren zur behandlung endo-ostealer materialien
DE69331469D1 (de) Verfahren zur behandlung von abfällen
EP1037625A4 (de) Verfahren zur herstellung von arsentrioxyd-formulierungen und verfahren zur behandlung von krebs mit arsentrioxyd oder melarsoprol
DE69730604D1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
DE69925266D1 (de) Verfahren und gerät zur behandlung von herzarhythmie
DE69112480D1 (de) Verfahren und Vorrichtung zur Behandlung von medizinischen Abfallstoffen.
DE69816070D1 (de) Verfahren zur Behandlung von Schredderstaub
DE69113681D1 (de) Verfahren und Vorrichtung zur Behandlung kontaminierter körniger Materialien.
DE69730097D1 (de) Verfahren und Vorrichtung zur Behandlung von Wafers
DE69829625D1 (de) Verfahren und Vorrichtung zur Behandlung von Perfluorokohlenstoff
DE69129194D1 (de) Vorrichtung und verfahren zur behandlung zellreicher suspensionen
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
ATE230617T1 (de) Verfahren und methode zur behandlung von abfällen
DE69714828D1 (de) Verfahren zur Behandlung von Abfallstoffen
DE69426485D1 (de) Verfahren und System zur Behandlung von verunreinigtem Wasser
DE69417018D1 (de) Verfahren zur behandlung von teilchenmaterial
DE69600480D1 (de) Verfahren und vorrichtung zur behandlung von aggregat
DE69518824D1 (de) Verfahren zur behandlung von bremsscheiben
DE69702997D1 (de) Verfahren zur Behandlung von verunreinigtem Aluminiumoxid
DE69328615D1 (de) Verfahren zur behandlung von viehhaltungsgülle
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer
DE69510990D1 (de) Verfahren und Vorrichtung zur Behandlung von metallichem Material

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0781136

Country of ref document: EP

REN Ceased due to non-payment of the annual fee